Axsome Therapeutics
AXSM
30 hedge funds and large institutions have $33.3M invested in Axsome Therapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 10 closing their positions.
1.67% less ownership
Funds ownership: 27.12% → 25.45% (-1.7%)
6% less capital invested
Capital invested by funds: $35.3M → $33.3M (-$1.97M)
14% less funds holding
Funds holding: 35 → 30 (-5)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$769K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$268K |
| 3 |
Squarepoint
New York
|
+$180K |
| 4 |
JP Morgan Chase
New York
|
+$125K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.22M |
| 2 |
SCM
Sio Capital Management
New York
|
-$880K |
| 3 |
Goldman Sachs
New York
|
-$372K |
| 4 |
ECM
Element Capital Management
New York
|
-$338K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$269K |
AXSM Hedge Fund Activity: Q3 2017 in Review
30 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2017, worth a combined $33.3M — down 5.6% from $35.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of AXSM and 5 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $769K. The largest seller was Fidelity Investments, cutting an estimated $1.22M.
- 30 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2017, down from 35 in Q2 2017.
- Funds reported $33.3M of Axsome Therapeutics stock for Q3 2017, down 5.6% quarter-over-quarter.
- 5 funds opened new Axsome Therapeutics positions in Q3 2017 and 10 closed out, a net change of -5 holders.
- The largest Axsome Therapeutics buyer in Q3 2017 was Vanguard Group, an estimated $769K added.
- The largest Axsome Therapeutics seller in Q3 2017 was Fidelity Investments, an estimated $1.22M sold.
Based on aggregated 13F filings for Q3 2017.